Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00522522 · ClinicalTrials.gov registry record

Naturalistic Study to Evaluate the Utilization of Care Services Associated to the Diagnostic Process of Any Kind of Epilepsy

A clinical trial, sponsored by UCB Pharma.

Completed
Registry status
400
Enrollment target

NCT00522522: Completed study, sponsored by UCB Pharma.

NCT00522522 is a clinical trial that has completed, run by UCB Pharma. The registered enrollment target is 400 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00522522 has completed, sponsored by UCB Pharma.

COMPLETED
Registry status
400 participants
Enrollment target

Study Summary

Naturalistic, multicentre, epidemiological study to evaluate the care services used during the process of diagnosis of any kind of epilepsy. Data about services since first seizure until confirmed diagnosis will be examined.

Trial Details

FieldValue
Enrollment Target 400 participants
Start Date 2008-02
Est. Completion 2008-07
UCB Pharma

100 total trials

What the finished NCT00522522 record still lists

NCT00522522 is an observational study that tracks outcomes without assigning an intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap.

The record links to 0 conditions, and to 0 interventions.

NCT00522522 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00522522 about?

NCT00522522 is a clinical study titled "Naturalistic Study to Evaluate the Utilization of Care Services Associated to the Diagnostic Process of Any Kind of Epilepsy". Naturalistic, multicentre, epidemiological study to evaluate the care services used during the process of diagnosis of any kind of epilepsy. Data about services since first seizure until confirmed diagnosis will be examined.

What is the current status of trial NCT00522522?

This trial is currently completed. The enrollment target is 400 participants. The study started on 2008-02. Estimated completion is 2008-07.

Who is sponsoring clinical trial NCT00522522?

This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01665326 · 400 participants

    Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease

  • NCT02108054 · 400 participants · NA

    Behavioral and Functional Task Development, Implementation, and Testing

  • NCT02216500 · 400 participants · NA

    Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy

  • NCT02250352 · 400 participants

    Core Biopsies for Establishing a Breast Tumor Tissue Repository

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00522522, the US trial registry maintained by the National Library of Medicine. NCT00522522 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.